225 related articles for article (PubMed ID: 1689212)
1. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.
Fendly BM; Winget M; Hudziak RM; Lipari MT; Napier MA; Ullrich A
Cancer Res; 1990 Mar; 50(5):1550-8. PubMed ID: 1689212
[TBL] [Abstract][Full Text] [Related]
2. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies.
Kita Y; Tseng J; Horan T; Wen J; Philo J; Chang D; Ratzkin B; Pacifici R; Brankow D; Hu S; Luo Y; Wen D; Arakawa T; Nicolson M
Biochem Biophys Res Commun; 1996 Sep; 226(1):59-69. PubMed ID: 8806592
[TBL] [Abstract][Full Text] [Related]
3. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.
Bacus SS; Stancovski I; Huberman E; Chin D; Hurwitz E; Mills GB; Ullrich A; Sela M; Yarden Y
Cancer Res; 1992 May; 52(9):2580-9. PubMed ID: 1373672
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
Ciardiello F; McGeady ML; Kim N; Basolo F; Hynes N; Langton BC; Yokozaki H; Saeki T; Elliott JW; Masui H
Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
Drebin JA; Link VC; Greene MI
Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
[TBL] [Abstract][Full Text] [Related]
6. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM
Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187
[TBL] [Abstract][Full Text] [Related]
7. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185.
McKenzie SJ; Marks PJ; Lam T; Morgan J; Panicali DL; Trimpe KL; Carney WP
Oncogene; 1989 May; 4(5):543-8. PubMed ID: 2566965
[TBL] [Abstract][Full Text] [Related]
8. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL
Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
[TBL] [Abstract][Full Text] [Related]
10. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
Stancovski I; Schindler DG; Waks T; Yarden Y; Sela M; Eshhar Z
J Immunol; 1993 Dec; 151(11):6577-82. PubMed ID: 7902379
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy.
Dougall WC; Qian X; Greene MI
J Cell Biochem; 1993 Sep; 53(1):61-73. PubMed ID: 7901229
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody.
Kern JA; Torney L; Weiner D; Gazdar A; Shepard HM; Fendly B
Am J Respir Cell Mol Biol; 1993 Oct; 9(4):448-54. PubMed ID: 8104437
[TBL] [Abstract][Full Text] [Related]
13. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer.
Fendly BM; Kotts C; Vetterlein D; Lewis GD; Winget M; Carver ME; Watson SR; Sarup J; Saks S; Ullrich A
J Biol Response Mod; 1990 Oct; 9(5):449-55. PubMed ID: 1979347
[TBL] [Abstract][Full Text] [Related]
14. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage.
Pupa SM; Ménard S; Morelli D; Pozzi B; De Palo G; Colnaghi MI
Oncogene; 1993 Nov; 8(11):2917-23. PubMed ID: 8105438
[TBL] [Abstract][Full Text] [Related]
15. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand.
Lonardo F; Di Marco E; King CR; Pierce JH; Segatto O; Aaronson SA; Di Fiore PP
New Biol; 1990 Nov; 2(11):992-1003. PubMed ID: 1983208
[TBL] [Abstract][Full Text] [Related]
16. A monoclonal antibody to the human epidermal growth factor receptor.
Waterfield MD; Mayes EL; Stroobant P; Bennet PL; Young S; Goodfellow PN; Banting GS; Ozanne B
J Cell Biochem; 1982; 20(2):149-61. PubMed ID: 6188757
[TBL] [Abstract][Full Text] [Related]
17. Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha.
Kumar R; Mendelsohn J
Anticancer Res; 1994; 14(3A):1001-8. PubMed ID: 7915505
[TBL] [Abstract][Full Text] [Related]
18. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
[TBL] [Abstract][Full Text] [Related]
20. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]